The discovery and development of perampanel for the treatment of epilepsy

Expert Opinion on Drug Discovery

Volumn 9, Issue 4, 2014, Pages 449-458

  Hanada, Takahisa ^a  

^a EISAI CO LTD   (Japan)

Author keywords

AMPA receptor antagonist; Anticonvulsant agent; Partial onset seizures; Perampanel; Refractory epilepsy

Indexed keywords

AMPA RECEPTOR; CENTRAL DEPRESSANT AGENT; GLUTAMATE RECEPTOR; PERAMPANEL; ANTICONVULSIVE AGENT; PYRIDONE DERIVATIVE;

AMYGDALOID NUCLEUS; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; BLOOD BRAIN BARRIER; CHEMICAL STRUCTURE; CLINICAL EVALUATION; COMPLEX PARTIAL SEIZURE; DEVELOPED COUNTRY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SCREENING; DRUG STABILITY; DRUG TOLERABILITY; DRUG TOLERANCE; EPILEPSY; EPILEPTIC STATE; HUMAN; MULTICENTER STUDY (TOPIC); NERVE CELL PLASTICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROTAROD TEST; SEIZURE THRESHOLD; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALS; ANTICONVULSANTS; EPILEPSY; HUMANS; PYRIDONES; RECEPTORS, AMPA;

EID: 84896913919     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.891580     Document Type: Review

References (67)

1. Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010;51:883-90
2. Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 2007;6:793-804
3. Shorvon SD, Goodridge DM. Longitudinal cohort studies of the prognosis of epilepsy: contribution of the National General Practice Study of Epilepsy and other studies. Brain 2013;136:3497-510
4. Löscher W, Schmidt D. Epilepsy: perampanel-new promise for refractory epilepsy? Nat Rev Neurol 2012;8:661-2
5. European Medicines Agency. Fycompa summary of product characteristics. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/EPAR- Product-Information/human/002434/WC500130815.pdf [Last accessed 24 October 2012]
6. Food and Drug Administration. Fycompa prescribing information. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/label/2012/202834lbl.pdf [Last accessed 5 November 2012]
7. Liu SQ, Cull-Candy SG. Synaptic activity at calcium-permeable AMPA receptors induces a switch in receptor subtype. Nature 2000;405:454-8
8. Rao VR, Finkbeiner S. NMDA and AMPA receptors: old channels, new tricks. Trends Neurosci 2007;30:284-91
9. Seeburg PH. The TINS/TiPS lecture. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci 1993;16:359-65
10. Tanaka H, Grooms SY, Bennett MV, Zukin RS. The AMPAR subunit GluR2: still front and center-stage. Brain Res 2000;886:190-207
11. Eid T, Kovacs I, Spencer DD, de Lanerolle NC. Novel expression of AMPA-receptor subunit GluR1 on mossy cells and CA3 pyramidal neurons in the human epileptogenic hippocampus. Eur J Neurosci 2002;15:517-27
12. Hosford DA, Crain BJ, Cao Z, et al. Increased AMPA-sensitive quisqualate receptor binding and reduced NMDA receptor binding in epileptic human hippocampus. J Neurosci 1991;11:428-34
13. Langer M, Brandt C, Zellinger C, Löscher W. Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology 2011;61:1033-47
14. Apland JP, Aroniadou-Anderjaska V, Figueiredo TH, et al. Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration. J Pharmacol Exp Ther 2013;344:133-40
15. Rakhade SN, Zhou C, Aujla PK, et al. Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures. J Neurosci 2008;28:7979-90
16. Dürmüller N, Craggs M, Meldrum BS. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res 1994;17:167-74
17. Namba T, Morimoto K, Sato K, et al. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res 1994;638:36-44
18. Rogawski MA, Kurzman PS, Yamaguchi SI, Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology 2001;40:28-35
19. Chapman AG, Smith SE, Meldrum BS. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res 1991;9:92-6
20. Turski L, Jacobsen P, Honore T, Stephens DN. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5- methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo (F)quinoxaline. J Pharmacol Exp Ther 1992;260:742-7
21. Yamaguchi S, Donevan SD, Rogawski MA. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res 1993;15:179-84
22. Honoré T, Davies SN, Drejer J, et al. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 1988;241:701-3
23. Tarnawa I, Farkas S, Berzsenyi P, et al. Electrophysiological studies with a 2,3- benzodiazepine muscle relaxant: GYKI 52466. Eur J Pharmacol 1989;167:193-9
24. Tarnawa I, Farkas S, Berzsenyi P, et al. Reflex inhibitory action of a non-NMDA type excitatory amino acid antagonist, GYKI 52466. Acta Physiol Hung 1990;75(Suppl):277-8
25. Weiser T. AMPA receptor antagonists for the treatment of stroke. Curr Drug Targets CNS Neurol Disord 2005;4:153-9
26. Langan YM, Lucas R, Jewell H, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia 2003;44:46-53
27. Walters MR, Kaste M, Lees KR, et al. The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebocontrolled safety and tolerability study. Cerebrovasc Dis 2005;20:304-9
28. Chappell AS, Sander JW, Brodie MJ, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002;58:1680-2
29. Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 2009;27:4155-61
30. Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:266-71
31. Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand 2013;127(Suppl 197):19-24
32. Hibi S, Ueno K, Nagato S, et al. Discovery of 2-(2-oxo-1-phenyl-5- pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile (perampanel): a novel, noncompetitive alpha-amino-3-hydroxy- 5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. J Med Chem 2012;55:10584-600
33. Miyaura N, Yamada K, Suzuki A. A new sterospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes. Tetrahedron Lett 1979;36:3437-40
34. Ceolin L, Bortolotto ZA, Bannister N, et al. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int 2012;61:517-22
35. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52:1331-40
36. Olney JW, Labruyere J, Wang G, et al. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991;254:1515-18
37. White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 2003;44(Suppl 7):2-8
38. Loscher W, Honack D, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 1991;8:171-89
39. Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001;47:217-27
40. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 2002;50:105-23
41. Wu T, Hanada T. Anti-seizure effect of perampanel in combination with other antiepileptic drugs (AEDs) in a rat amygdala kindling model. Poster P202 presented at the 30th International Epilepsy Congress; 23 - 27 June; Montreal, Canada
42. Ido K, Hanada T. Therapeutic time window of perampanel for the termination of diazepam resistant status epilepticus (SE) in a lithium pilocarpine rat model. Poster P203 presented at the 30th International Epilepsy Congress; 23 - 27 June; Montreal, Canada
43. French JA, Faught E. Rational polytherapy. Epilepsia 2009;50(Suppl 8):63-8
44. Yamashita H, Ohno K, Amada Y, et al. Effects of 2-[N-(4-chlorophenyl)- Nmethylamino]- 4H-pyrido[3.2-e]-1,3- thiazin-4-one (YM928), an orally active alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats. J Pharmacol Exp Ther 2004;308:127-33
45. DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 2003;37(Suppl 2):25-42
46. Dalby NO, Nielsen EB. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res 1997;28:63-72
47. Vartanian MG, Radulovic LL, Kinsora JJ, et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res 2006;68:189-205
48. Anhut H, Ashman P, Feuerstein TJ, et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994;35:795-801
49. Kwan P, Brodie MJ, Kälviäinen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011;10:881-90
50. Beydoun A, Uthman BM, Kugler AR, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005;64:475-80
51. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebocontrolled, dose-response study in adults with partial seizures. Epilepsia 2004;45:20-7
52. Stepien K, Tomaszewski M, Tomaszewska J, Czuczwar SJ. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep 2012;64:1011-19
53. Templeton D. Pharmacokinetics of perampanel, a highly selective AMPAtype glutamate receptor antagonist [abstract 1.199]. Epilepsia 2009;50(Suppl 11):98
54. Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125:8-15
55. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589-96
56. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54:117-25
57. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-15
58. Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013;54:1481-9
59. Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia 2013;54:1490-7
60. Kwan P, Brodie M, Squillacote D, et al. Adjunctive perampanel is effective against partial seizures, irrespective of concomitant antiepileptic drugs (AEDs): a pooled analysis of three Phase III trials. Abstract 1.239 presented at the 66th American Epilepsy Society Annual Meeting; 30 November - 4 December 2012; San Diego, CA, USA
61. Serratosa JM, Villanueva V, Kerling F, Kasper BS. Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand 2013;127(Suppl 197):30-5
62. Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126:263-9
63. Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive alpha-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia 2013;54:126-34
64. Lees A, Fahn S, Eggert KM, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord 2012;27:284-8
65. ClinicalTrials.gov. An evaluation of the efficacy and safety of E2007 in patients with painful diabetic neuropathy. Available from: http:// clinicaltrials.gov/ct2/show/results/NCT00505284 [Last accessed 21 October 2013]
66. ClinicalTrials.gov. Dose-tolerability titration study to evaluate the efficacy and safety of perampanel (E2007) in patients with post-herpetic neuralgia (PHN). Available from: http://clinicaltrials.gov/ct2/show/results/ NCT00592774 [Last accessed 21 October 2013]
67. Ko D, Ramsay RE. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures. Acta Neurol Scand Suppl 2013;127:36-43